These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32580152)

  • 1. Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use.
    Goto Y; Otsuka Y; Ashida K; Nagayama A; Hasuzawa N; Iwata S; Hara K; Tsuruta M; Wada N; Motomura S; Tajiri Y; Nomura M
    Endocr Connect; 2020 Jul; 9(7):599-606. PubMed ID: 32580152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus.
    Koike Y; Shirabe SI; Maeda H; Yoshimoto A; Arai K; Kumakura A; Hirao K; Terauchi Y
    Diabetes Res Clin Pract; 2019 Mar; 149():140-146. PubMed ID: 30716347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
    Kern M; Klöting N; Mark M; Mayoux E; Klein T; Blüher M
    Metabolism; 2016 Feb; 65(2):114-23. PubMed ID: 26773934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of exenatide therapy on insulin resistance in the skeletal muscles of high-fat diet and low-dose streptozotocin-induced diabetic rats.
    Wu H; Sui C; Xia F; Zhai H; Zhang H; Xu H; Weng P; Lu Y
    Endocr Res; 2016; 41(1):1-7. PubMed ID: 26361069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
    Nagayama A; Ashida K; Watanabe M; Moritaka K; Sonezaki A; Kitajima Y; Takahashi H; Yoshinobu S; Iwata S; Yasuda J; Hasuzawa N; Ozono S; Motomura S; Nomura M
    Front Endocrinol (Lausanne); 2021; 12():690996. PubMed ID: 34135866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Type 1 Diabetes Mellitus on Body Composition and Glucose Variabilities: Single-Arm, Exploratory Trial.
    Baba Y; Ishibashi R; Takasaki A; Ito C; Watanabe A; Tokita M; Meguro M; Harama T; Hirayama K; Yamamoto T; Nakamura S; Koshizaka M; Maezawa Y; Uchida D; Okajima F
    Diabetes Ther; 2021 May; 12(5):1415-1427. PubMed ID: 33738773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correcting Postprandial Hyperglycemia in Zucker Diabetic Fatty Rats With an SGLT2 Inhibitor Restores Glucose Effectiveness in the Liver and Reduces Insulin Resistance in Skeletal Muscle.
    O'Brien TP; Jenkins EC; Estes SK; Castaneda AV; Ueta K; Farmer TD; Puglisi AE; Swift LL; Printz RL; Shiota M
    Diabetes; 2017 May; 66(5):1172-1184. PubMed ID: 28246292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Branched-chain amino acid metabolism, insulin sensitivity and liver fat response to exercise training in sedentary dysglycaemic and normoglycaemic men.
    Lee S; Gulseth HL; Langleite TM; Norheim F; Olsen T; Refsum H; Jensen J; Birkeland KI; Drevon CA
    Diabetologia; 2021 Feb; 64(2):410-423. PubMed ID: 33123769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes.
    Sato M; Tamura Y; Kaga H; Yamasaki N; Kiya M; Kadowaki S; Sugimoto D; Funayama T; Someya Y; Kakehi S; Nojiri S; Satoh H; Kawamori R; Watada H
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center.
    Sugiyama S; Jinnouchi H; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    J Clin Med Res; 2019 Apr; 11(4):267-274. PubMed ID: 30937117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients.
    Al Jobori H; Daniele G; Adams J; Cersosimo E; Triplitt C; DeFronzo RA; Abdul-Ghani M
    Diabetes Obes Metab; 2017 Jun; 19(6):809-813. PubMed ID: 28128510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of an early decline in baseline plasma glucose concentration after acute insulin elevation during euglycemic hyperinsulinemic clamp in patients with type 2 diabetes mellitus.
    Wasada T; Kuroki H; Arii H; Sato A; Katsumori K; Saito S; Iwamoto Y
    Endocr J; 2000 Jun; 47(3):309-16. PubMed ID: 11036875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.
    Yan PK; Zhang LN; Feng Y; Qu H; Qin L; Zhang LS; Leng Y
    Acta Pharmacol Sin; 2014 May; 35(5):613-24. PubMed ID: 24786232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis of randomized controlled trials.
    Yang Y; Chen S; Pan H; Zou Y; Wang B; Wang G; Zhu H
    Medicine (Baltimore); 2017 May; 96(21):e6944. PubMed ID: 28538386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study.
    Liu SC; Lee CC; Chuang SM; Sun FJ; Zeng YH
    Diabetes Metab; 2021 May; 47(3):101184. PubMed ID: 32827752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
    Neumiller JJ
    Drugs Context; 2014; 3():212262. PubMed ID: 24991224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between expression of FABPpm in skeletal muscle and insulin sensitivity in intramyocellular lipid-accumulated nonobese men.
    Kawaguchi M; Tamura Y; Kakehi S; Takeno K; Sakurai Y; Watanabe T; Funayama T; Sato F; Ikeda S; Ogura Y; Saga N; Naito H; Fujitani Y; Kanazawa A; Kawamori R; Watada H
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3343-52. PubMed ID: 24937540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.